This is an old revision of this page, as edited by Roadcreature (talk | contribs) at 14:43, 14 January 2008 (tagging disputed section). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 14:43, 14 January 2008 by Roadcreature (talk | contribs) (tagging disputed section)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Medical conditionFibromyalgia |
---|
Fibromyalgia (FM) is a disorder classified by the presence of chronic widespread pain and tactile allodynia. Fibromyalgia patients are also typically affected by a number of symptoms other than pain, including debilitating fatigue, abnormal sleep architecture, functional bowel disturbances and a variety of neuropsychiatric problems including cognitive dysfunction, anxiety and depressive symptoms. While the criteria for such an entity has not yet been thoroughly developed, the recognition that fibromyalgia involves more than just pain has led to the frequent use of the term “fibromyalgia syndrome.” It is not contagious, and recent studies suggest that people with fibromyalgia may be genetically predisposed. It affects more females than males, with a ratio of 9:1 by American College of Rheumatology (ACR)criteria. Fibromyalgia is seen in about 2% of the general population. It is most commonly diagnosed in individuals between the ages of 20 and 50, though onset can occur in childhood.
The disorder is not directly life-threatening. The degree of symptoms may vary greatly from day to day with periods of flares (severe worsening of symptoms) or remission; however, the disorder is generally perceived as non-progressive.
This article may contain citations that do not verify the text. Please check for citation inaccuracies. (Learn how and when to remove this message) |
The neutrality of this section is disputed. Relevant discussion may be found on the talk page. Please do not remove this message until conditions to do so are met. (Learn how and when to remove this message) |
The disease we know as Fibromyalgia is poorly understood and may actually be composed of several different diseases presenting with similar symptoms. These diseases may range from a mild inflammatory process of unknown cause in some individuals, to a somatoform disorder resulting from clinical depression in other individuals, with probable overlaps in between. Current diagnostic criteria are insufficient to differentiate patient groups from each other.
History
Fibromyalgia has been studied since the early 1800s and referred to by a variety of former names, including muscular rheumatism and fibrositis. The term fibromyalgia was coined in 1976 to more accurately describe the symptoms, from the Latin fibra (fiber) and the Greek words myo (muscle) and algos (pain).
In 1981, Dr. Muhammad B. Yunus published the "first controlled study of the clinical characteristics" of the fibromyalgia syndrome, for which he is considered "the father of our modern view of fibromyalgia." His work was the "first controlled clinical study" of fibromyalgia with validation of known symptoms and tender points, and he also proposed "the first data-based criteria." In 1984, he proposed the important concept that the fibromyalgia syndrome and other similar conditions are interconnected. In 1986, he showed serotonergic and norepinephric drugs to be effective.
Fibromyalgia was recognized by the American Medical Association as an illness and a cause of disability in 1987. In an article the same year, in the Journal of the American Medical Association, a physician named Dr. Don Goldenberg also called the disorder fibromyalgia.
Muhammad B. Yunus and his colleagues at the American College of Rheumatology published a criteria for fibromyalgia in 1990, and developed neurohormonal mechanisms with central sensitization in the 1990s. Muhammad B. Yunus later emphasized a "biopsychosocial perspective" of fibromyalgia, which is considered the "only way to synthesize the disparate contributions of such variables as genes and adverse childhood experiences, life stress and distress, posttraumatic stress disorder, mood disorders, self-efficacy for pain control, catastrophizing, coping style, and social support into the evolving picture of central nervous system dysfunction vis-a-vis chronic pain and fatigue."
Symptoms
The defining symptoms of fibromyalgia are chronic, widespread pain and tenderness to light touch. There is also typically moderate to severe fatigue. Those affected may also experience heightened sensitivity of the skin (also called allodynia), tingling of the skin (often needle-like), achiness in the muscle tissues, prolonged muscle spasms, weakness in the limbs, and nerve pain. Chronic sleep disturbances are also characteristic of fibromyalgia. Indeed, studies suggest that sleep disturbance are related to a phenomenon called alpha-delta sleep, a condition in which deep sleep (associated with delta EEG waves) is frequently interrupted by bursts of brain activity similar to wakefulness (i.e. alpha waves). Deeper stages of sleep (stages 3 & 4) are often dramatically reduced.
In addition, many patients experience cognitive dysfunction (known as "brain fog" or "fibrofog"), which may be characterized by impaired concentration and short-term memory consolidation, impaired speed of performance, inability to multi-task, and cognitive overload. Many experts suspect that "brain fog" is directly related to the sleep disturbances experienced by sufferers of fibromyalgia. However, the relationship has not been strictly established.
Other symptoms often attributed to fibromyalgia that may possibly be due to a comorbid disorder include myofascial pain syndrome, diffuse non-dermatomal paresthesias, functional bowel disturbances and irritable bowel syndrome, genitourinary symptoms and interstitial cystitis), dermatological disorders, headaches, myoclonic twitches, and symptomatic hypoglycemia. Although fibromyalgia is classified based on the presence of chronic widespread pain, pain may also be localized in areas such as the shoulders, neck, low back, hips, or other areas. Many sufferers also experience varying degrees of facial pain and have high rates of comorbid temporomandibular joint disorder. Not all patients have all symptoms.
Symptoms can have a slow onset, and many patients have mild symptoms beginning in childhood, that are often misdiagnosed as growing pains. Symptoms are often aggravated by unrelated illness or changes in the weather. They can become more tolerable or less tolerable throughout daily or yearly cycles; however, many people with fibromyalgia find that, at least some of the time, the condition prevents them from performing normal activities such as driving a car or walking up stairs. The disorder does not cause inflammation as is characteristic of rheumatoid arthritis, although some NSAIDs may temporarily reduce pain symptoms in some patients. Their use, however, is limited, and often of little to no value in pain management.
Variability of symptoms
The following factors have been proposed to exacerbate symptoms of pain in patients:
- Increased psychosocial stress
- Excessive physical exertion (exercise seems to decrease the pain threshold of people with Fibromyalgia but increase it in healthy individuals)
- Lack of slow-wave sleep
- Changes in humidity and barometric pressure
Proposed causes and pathophysiology
The cause of fibromyalgia is unknown. Fibromyalgia can, but does not always, start as a result of some trauma such as a traffic accident, major surgery, or disease. Some evidence shows that Lyme Disease may be a trigger of fibromyalgia symptoms. Another study suggests that more than one clinical entity may be involved, ranging from a mild, idiopathic inflammatory process to clinical depression
Genetics
By using self-reported "Chronic Widespread Pain" (CWP) as a surrogate marker for fibromyalgia, the Swedish Twin Registry found that a modest genetic contribution may exist:
- Monozygotic twins with CWP have a 15% chance that their twin sibling has CWP
- Dizygotic twins with CWP have a 7% chance that their twin sibling has CWP
Stress
Studies have shown that stress is a significant precipitating factor in the development of fibromyalgia, and that PTSD is linked with fibromyalgia. The Amital study found that 49% of PTSD patients fulfilled the criteria for FMS, compared with none of the controls.
Related to this is the idea that fibromyalgia may be a psychosomatic illness. One controversial hypothesis of this nature has been popularized in the books of Dr. John E. Sarno, as a hypothetical condition to which Dr. Sarno has given the name of "tension myositis syndrome". Dr. Sarno's hypothesis claims that in many cases chronic pain is the result of physical changes in the body caused by a person's subconscious as a strategy for distracting from painful or dangerous unconscious emotions, such as repressed anger. Dr. Sarno believes that this can be treated through a program of education and attitude change (and in some cases, psychotherapy) which stops the brain from using that chronic pain strategy.
Dopamine abnormality
Dopamine is a catecholamine neurotransmitter perhaps best known for its role in the pathology of schizophrenia, Parkinson's disease and addiction. There is also strong evidence for a role of dopamine in restless leg syndrome , which is a common co-morbid condition in patients with fibromyalgia. In addition, dopamine plays a critical role in pain perception and natural analgesia. Accordingly, musculoskeletal pain complaints are common among patients with Parkinson's disease , which is characterized by drastic reductions in dopamine owing to neurodegeneration of dopamine-producing neurons, while patients with schizophrenia, which is thought to be due (in part) to hyperactivity of dopamine-producing neurons, have been shown to be relatively insensitive to pain. Interestingly, patients with restless legs syndrome have also been demonstrated to have hyperalgesia to static mechanical stimulation.
Fibromyalgia has been commonly referred to as a "stress-related disorder" due to its frequent onset and worsening of symptoms in the context of stressful events. It was therefore proposed that fibromyalgia may represent a condition characterized by low levels of central dopamine that likely results from a combination of genetic factors and exposure to environmental stressors, including psychosocial distress, physical trauma, systemic viral infections or inflammatory disorders (e.g. rheumatoid arthritis, systemic lupus erythematosus). This conclusion was based on three key observations: (1) fibromyalgia is associated with stress; (2) chronic exposure to stress results in a disruption of dopamine-related neurotransmission; and (3) dopamine is plays a critical role in modulating pain perception and central analgesia in such areas as the basal ganglia including the nucleus accumbens, insular cortex, anterior cingulate cortex, thalamus, periaqueductal gray, and spinal cord .
In support of the 'dopamine hypothesis of fibromyalgia', a reduction in dopamine synthesis has been reported by a study that used positron emission tomography (PET) and demonstrated a reduction in dopamine synthesis among fibromyalgia patients in several brain regions in which dopamine plays a role in inhibiting pain perception, including the mesencephalon, thalamus, insular cortex and anterior cingulate cortex. A subsequent PET study demonstrated that, whereas healthy individuals release dopamine into the caudate nucleus and putamen during a tonic experimental pain stimulus (i.e. hypertonic saline infusion into a muscle bed), fibromyalgia patients fail to release dopamine in response to pain and, in some cases, actually have a reduction in dopamine levels during painful stimulation. Moreover, a substantial subset of fibromyalgia patients respond well in controlled trials to pramipexole, a dopamine agonist that selectively stimulates dopamine D2/D3 receptors and is used to treat both Parkinson's disease and restless legs syndrome. Trials of other dopamine agonists are currently on going.
Serotonin
Serotonin is a neurotransmitter that is known to play a role in regulating sleep patterns, mood, feelings of well-being, concentration and descending inhibition of pain. Accordingly, it has been hypothesized that the pathophysiology underlying the symptoms of fibromyalgia may be a dysregulation of serotonin metabolism, which may explain (in part) many of the symptoms associated with the disorder. This hypothesis is derived in part by the observation of decreased serotonin metabolites in patient plasma and cerebrospinal fluid. However, selective serotonin reuptake inhibitors (SSRIs) have met with limited success in alleviating the symptoms of the disorder, while drugs with activity as mixed serotonin-norepinephrine reuptake inhibitors (SNRIs) have been more successful. Accordingly, duloxetine (Cymbalta), a SNRI originally used to treat depression and painful diabetic neuropathy, has been demonstrated by controlled trials to relieve symptoms of some patients. Eli Lilly and Company, the manufacturer of duloxetine has submitted a supplementary new drug application (sNDA) to the FDA for approval of it use in the treatment of FM. The relevance of dysregulated serotonin metabolism to the pathophysiology is a matter of debate. Ironically, one of the more effective types of medication for the treatment of the disorder (i.e. serotonin 5-HT3 antagonists) actually block some of the effects of serotonin.
Sleep disturbance
Electroencephalography studies have shown that people with fibromyalgia lack of slow-wave sleep and circumstances that interfere with stage four sleep (pain, depression, serotonin deficiency, certain medications or anxiety) may cause or worsen the condition. According to the sleep disturbance hypothesis, an event such as a trauma or illness causes sleep disturbance and possibly initial chronic pain that may initiate the disorder. The hypothesis supposes that stage 4 sleep is critical to the function of the nervous system, as it is during that stage that certain neurochemical processes in the body 'reset'. In particular, pain causes the release of the neuropeptide substance P in the spinal cord which has the effect of amplifying pain and causing nerves near the initiating ones to become more sensitive to pain. Under normal circumstances, areas around a wound to become more sensitive to pain but if pain becomes chronic and body-wide this process can run out of control. The sleep disturbance hypothesis holds that deep sleep is critical to reset the substance P mechanism and prevent this out-of-control effect.
The sleep disturbance/substance P hypothesis could explain "tender points" that are characteristic of fibromyalgia but which are otherwise enigmatic, since their positions don't correspond to any particular set of nerve junctions or other obvious body structures. The hypothesis proposes that these locations are more sensitive because the sensory nerves that serve them are positioned in the spinal cord to be most strongly affected by substance P. This hypothesis could also explain some of more general neurological features of fibromyalgia, since substance P is active in many other areas of the nervous system. The sleep disturbance hypothesis could also provide a possible connection between fibromyalgia, chronic fatigue syndrome (CFS) and post-polio syndrome through damage to the ascending reticular activating system of the reticular formation. This area of the brain, in addition to apparently controlling the sensation of fatigue, is known to control sleep behaviors and is also believed to produce some neuropeptides, and thus injury or imbalance in this area could cause both CFS and sleep-related fibromyalgia.
Critics of the hypothesis argue that it does not explain slow-onset fibromyalgia, fibromyalgia present without tender points, or patients without heightened pain symptoms, and a number of the non-pain symptoms present in the disorder.
Human growth hormone
An alternate hypothesis suggests that stress-induced problems in the hypothalamus may lead to reduced sleep and reduced production of human growth hormone (HGH) during slow-wave sleep. People with fibromyalgia tend to produce inadequate levels of HGH. Most patients with FM with low IGF-I levels failed to secrete HGH after stimulation with clonidine and l-dopa.
This view is supported by the fact that those hormones under the direct or indirect control of HGH, including IGF-1, cortisol, leptin and neuropeptide Y are abnormal in people with fibromyalgia, In addition, treatment with exogenous HGH or growth hormone secretagogue reduces fibromyalgia related pain and restores slow wave sleep though there is disagreement about the proposition.
Deposition disease
The 'deposition hypothesis of fibromyaglia' posits fibromyalgia is due to intracellular phosphate and calcium accumulations that eventually reache levels sufficient to impede the ATP process, possibly caused by a kidney defect or missing enzyme that prevents the removal of excess phosphates from the blood stream. Accordingly, proponents of this hypothesis suggest that fibromyalgia may be an inherited disorder, and that phosphate build-up in cells is gradual but can be accelerated by trauma or illness. Calcium is required for the excess phosphate to enter the cells.The additional phosphate slows down the ATP process; however the excess calcium prods the cell to continue producing ATP.
Diagnosis is made with a specialized technique called mapping, a gentle palpitation of the muscles to detect lumps and areas of spasm thought to be caused by an excess of calcium in the cytosol of the cells. The mapping technique is notably different from the manual tenderpoint examination upon which a diagnosis of fibromyalgia depends and is purportedly different from the detection of trigger points that characterize the myofascial pain syndrome.
While this hypothesis does not identify the causative mechanism in the kidneys, it proposes a treatment known as guaifenesin therapy. This treatment involves administering the drug guaifenesin to a patient's individual dosage, avoiding salicylic acid in medications or on the skin. Often products for salicylate sensitivity are very helpful. If the patient is also hypoglycemic, a diet is designed to keep insulin levels low.
The phosphate build-up hypothesis explains many of the symptoms present in fibromyalgia.and proposes an underlying cause. The guaifenesin treatment, based on this hypothesis, has received mixed reviews, with some practitioners claiming many near-universal successes and others reporting no success. Of note, guaifenesin is also a central acting muscle relaxant used in veterinary anaesthesia that is structurally related to methocarbamol, a property that might explain its utility in some fibromyalgia patients. A controlled trial of guaifenesin for the treatment of fibromyalgia demonstrated no evidence for efficacy of this medication. However, this study has been criticized by the chief proponent of the deposition hypothesis for not limiting salicylic acid exposure in patients, and for studying the effectiveness of only guaifenesin, not the entire treatment method. As of 2005, further studies to test the protocol's effectiveness are in the planning stages, with funding for independent studies largely collected from groups which advocate the hypothesis. It should be noted that nothing in the scientific literature supports the proposition that fibromyalgia patients have excessive levels of phosphate in their tissues.
Other hypotheses
Other hypotheses have been proposed related to various toxins from the patient's environment, viral causes such as the Epstein-Barr Virus, growth hormone deficiencies possibly related to an underlying (maybe autoimmune) disease affecting the hypothalamus gland, an aberrant immune response to intestinal bacteria, neurotransmitter disruptions in the central nervous system, and erosion of the protective chemical coating around sensory nerves. A 2001 study suggested an increase in fibromyalgia among women with extracapsular silicone gel leakage, compared to women whose implants were not broken or leaking outside the capsule. This association has not repeated in a number of related studies, and the US-FDA concluded "the weight of the epidemiological evidence published in the literature does not support an association between fibromyalgia and breast implants." Due to the multi-systemic nature of illnesses such as fibromyalgia and chronic fatigue syndrome (CFS/ME), an emerging branch of medical science called psychoneuroimmunology (PNI) is looking into how the various hypotheses fit together.
Another hypothesis on the cause of symptoms in fibromyalgia states that patients suffer from vasomotor dysregulation causing improper vascularflow and hypoperfusion (decreased blood flow to a given tissue or organ).
Always a comorbid disease?
Cutting across several of the above hypotheses is the proposition that fibromyalgia is almost always a comorbid disorder, occurring in combination with some other disorder that likely served to "trigger" the fibromyalgia in the first place. Two possible triggers are gluten sensitivity and/or irritable bowel. Irritable bowel is found at high frequency in fibromyalgia, and a large coeliac support group survey of adult celiacs revealed that 7% had fibromyalgia and also has a co-occurrence with chronic fatique.
According to this hypothesis, some other disorder (or trauma) occurs first, and fibromyalgia follows as a result. In some cases, the original disorder abates on its own or is separately treated and cured, but the fibromyalgia remains. This is especially apparent when fibromyalgia seems triggered by major surgery. In other cases the two disorders coexist.
Diagnosis
There is still debate over what should be considered essential diagnostic criteria. The most widely accepted set of classification criteria for research purposes were elaborated in 1990 by the Multicenter Criteria Committee of the the American College of Rheumatology. These criteria, which are known informally as "the ACR 1990" define fibromyalgia according to the presence of the following criteria:
- A history of widespread pain lasting more than three months—affecting all four quadrants of the body, i.e., both sides, and above and below the waist.
- Tender points—there are 18 designated possible tender or trigger points (although a person with the disorder may feel pain in other areas as well). During diagnosis, four kilograms-force (39 newtons) of force is exerted at each of the 18 points; the patient must feel pain at 11 or more of these points for fibromyalgia to be considered. Four kilograms of force is about the amount of pressure required to blanch the thumbnail when applying pressure. This set of criteria was developed by the American College of Rheumatology as a means of classifying an individual as having fibromyalgia for both clinical and research purposes. While these criteria for classification of patients were originally established as inclusion criteria for research purposes and were not intended for clinical diagnosis, they have become the de facto diagnostic criteria in the clinical setting. It should be noted that the number of tender points that may be active at any one time may vary with time and circumstance.
Differentials
A number of other disorders can produce similar symptoms to fibromyalgia:
- Chronic fatigue syndrome
- Depression
- Ehlers-Danlos syndrome
- Gulf War syndrome
- Influenza
- Lead poisoning
| class="col-break " |
| class="col-break " |
- Thyroid disease
- Vitamin B12 deficiency
- Vitamin D deficiency
- Whiplash-associated disorder
- Multiple chemical sensitivity
Treatment
As with many other syndromes, there is no universally accepted cure for fibromyalgia, though some physicians claim to have found cures. However, a steady interest in the disorder on the part of academic researchers as well as pharmaceutical interests has led to improvements in its treatment, which ranges from symptomatic prescription medication to alternative and complementary medicine.
Medications
Many medications are used to treat specific symptoms of fibromyalgia, such as muscle pain and insomnia.
Pain Relief
A number of pain relievers have been prescribed for fibromyalgia. This includes NSAID medications over the counter, COX-2 inhibitors, and tramadol in prescription form for more advanced cases.
Muscle Relaxants
Muscle relaxants, such as cyclobenzaprine or tizanidine, may be used to treat the muscle pain associated with the disorder.
Tricyclic antidepressants (TCAs)
Traditionally, low doses of sedating antidepressants (e.g. amitriptyline and trazodone) have been used to reduce the sleep disturbances that are associated with fibromyalgia and are believed by some practitioners to alleviate the symptoms of the disorder. Because depression often accompanies chronic illness, these antidepressants may provide additional benefits to patients suffering from depression. Amitriptyline is often favoured as it can also have the effect of providing relief from neuralgenic or neuropathic pain. It is to be noted that Fibromyalgia is not considered a depressive disorder; antidepressants are used for their sedating effect to aid in sleep.
Selective serotonin reuptake inhibitors (SSRIs)
Standard clinical doses of newer anti-depressants (SSRIs) like Citalopram (Celexa) have demonstrated good efficacy in some cases of fibromyalgia. Other data contradict the utility of agents with greater specificity as serotonin reuptake inhibitors
Anti-seizure drugs
Anti-seizure drugs are also sometimes used, such as gabapentin and pregabalin (Lyrica). Pregabalin, originally used for the nerve pain suffered by diabetics, has been approved by the American Food and Drug Administration for treatment of fibromyalgia. A randomized controlled trial of pregabalin 450 mg/day found that a number needed to treat of 6 patients for one patient to have 50% reduction in pain.
Dopamine agonists
Dopamine agonists (e.g. pramipexole (Mirapex) and ropinirole(ReQuip)) have been studied for use in the treatment of fibromyalgia with good results. A trial of transdermal rotigotine is currently on going .
Combination therapy
A controlled clinical trial of amitriptyline and fluoxetine demonstrated utility when used in combination.
Cannabis and cannabinoids
Fibromyalgia patients frequently self-report using cannabis therapeutically to treat symptoms of the disorder. Writing in the July 2006 issue of the journal Current Medical Research and Opinion, investigators at Germany's University of Heidelberg evaluated the analgesic effects of oral THC (∆-tetrahydrocannabinol) in nine patients with fibromyalgia over a 3-month period. Subjects in the trial were administered daily doses of 2.5 to 15 mg of THC, but received no other pain medication during the trial. Among those participants who completed the trial, all reported a significant reduction in daily recorded pain and electronically induced pain. Previous clinical and preclinical trials have shown that both naturally occurring and endogenous cannabinoids hold analgesic qualities, particularly in the treatment of cancer pain and neuropathic pain, both of which are poorly treated by conventional opioids. As a result, some experts have suggested that cannabinoid agonists would be applicable for the treatment of chronic pain conditions unresponsive to opioid analgesics such as fibromyalgia, and they propose that the disorder may be associated with an underlying clinical deficiency of the endocannabinoid system.
Topical Remedies
Users of Epsom Salts in the gel form (Magnesium Sulfate), have reported significant and lasting relief from pain associated with fibromyalgia. Epsom Salts have long been touted for its ability to reduce pain and swelling.
Non-drug treatment
Physical treatments
Studies have found exercise improves fitness and sleep and may reduce pain and fatigue in some people with fibromyalgia. Many patients find temporary relief by applying heat to painful areas. Those with access to physical therapy, massage, acupuncture may find them beneficial. Most patients find exercise, even low intensity exercise to be extremely helpful. Osteopathic manipulative therapy can also temporarily relieve pain due to fibromyalgia.
A holistic approach—including managing diet, sleep, stress, activity, and pain—is used by many patients. Dietary supplements, massage, chiropractic care, managing blood sugar levels, and avoiding known triggers when possible means living as well as it is in the patient's power to do.
Psychological/Behavioral Therapies
As the nature of fibromyalgia is not well understood, some physicians believe that it may be psychosomatic or psychogenic. Although there is no universally accepted cure, some doctors have claimed to have successfully treated fibromyalgia when a psychological cause is accepted.
Cognitive behavioral therapy has been shown to improve quality of life and coping in fibromyalgia patients and other sufferers of chronic pain. Neurofeedback has also shown to provide temporary and long-term relief.
Treatment for the "brain fog" has not yet been developed, however biofeedback and self-management techniques such as pacing and stress management may be helpful for some patients. The use of medication to improve sleep helps some patients, as does supplementation with folic acid and ginkgo biloba.
Dietary treatment
In a 2001 review of four case studies, symptom alleviation was found by minimising consumption of sodium glutamate.
Investigational treatments
Milnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), is available in parts of Europe where it has been safely prescribed for other disorders. On May 22nd, 2007, a Phase III study demonstrated statistically significant therapeutic effects of Milnacipran as a treatment of fibromyalgia syndrome. At this time, only initial top-line results are available and further analyses will be completed in the coming weeks. If ultimately approved by the FDA, Milnacipran could be distributed in the United States as early as summer, 2008.
Among the more controversial therapies involves the use of guaifenesin; called St. Amand's protocol or the guaifenesin protocol the efficacy of guaifenesin in treating fibromyalgia has not been proven in properly designed research studies. Indeed, a controlled study conducted by researchers at Oregon Health Science University in Portland failed to demonstrate any benefits from this treatment, and the lead researcher has suggested that the annecdotaly reported benefits where due to placebo suggestion. The results of the study have since been contested by Dr St. Amand, who was a co-author or the original research report.
Dextromethorphan is an over-the-counter cough medicine with activity as an NMDA receptor antagonist. It has been used in the research setting to investigate the nature of fibromyalgia pain; however, there are no controlled trials of safety or efficacy in clinical use.
Living with fibromyalgia
Fibromyalgia can affect every aspect of a person's life. While neither degenerative nor fatal, the chronic pain associated with fibromyalgia is pervasive and persistent. FMS can severely curtail social activity and recreation, and as many as 30% of those diagnosed with fibromyalgia are unable to maintain full-time employment. Like others with disabilities, individuals with FMS often need accommodations to fully participate in their education or remain active in their careers.
In the United States, those who are unable to maintain a full-time job due to the condition may apply for Social Security Disability benefits. Although fibromyalgia has been recognized as a genuine, severe medical condition by the government, applicants are often denied benefits, since there are no formal diagnostic criteria or medically provable symptoms. Because of this, if an applicant does have a medically verifiable condition that would justify disability benefits in addition to fibromyalgia, it is recommended that they not list fibromyalgia in their claim. However, most are awarded benefits at the judicial level; the entire process often takes two to four years.
In the United Kingdom, the Department for Work and Pensions recognizes fibromyalgia as a condition for the purpose of claiming benefits and assistance.
Fibromyalgia is often referred to as an "invisible" illness or disability due to the fact that generally there are no outward indications of the illness or its resulting disabilities. The invisible nature of the illness, as well as its relative rarity and the lack of understanding about its pathology, often has psychosocial complications for those that have the disorder. Individuals suffering from invisible illnesses in general often face disbelief or accusations of malingering or laziness from others that are unfamiliar with the disorder.
There are a variety of support groups on the Web that cater to fibromyalgia sufferers.
References
- http://www.ncbi.nlm.nih.gov/pubmed/2306288?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/169541?ordinalpos=40&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/15361320?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/17092441?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/17894922?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16887010
- Fibromyalgia med/790 at eMedicine
- ^ Chakrabarty, S (July 2007). "Fibromyalgia". American Family Physician. 76 (2): 247–254. PMID 17695569. Retrieved 2008-01-06.
{{cite journal}}
: Unknown parameter|coauthors=
ignored (|author=
suggested) (help) - McBride CR (03 Jul 2000). "Fibromyalgia". Clinical Vignette. UCLA Department of Medicine.
{{cite web}}
: Check date values in:|date=
(help) - http://www.springerlink.com/content/1271314042w8405g/ Mueller W, et al. The classification of fibromyalgia syndrome. Rheumatol Int. 2007 Jul 25
- The association or otherwise of the functional somatic syndromes.Psychosom Med. 2007 Dec;69(9):855-9. Review. PMID: 180400
- Comorbidity of fibromyalgia and psychiatric disorders.Curr Pain Headache Rep. 2007 Oct;11(5):333-8. Review. PMID: 17894922
- An integrated model of group psychotherapy for patients with fibromyalgia.Int J Group Psychother. 2007 Oct;57(4):451-74
- Health Information Team (February 2004). "Fibromyalgia".
{{cite web}}
: Unknown parameter|Publisher=
ignored (|publisher=
suggested) (help) - Meaning of fibra
- Meaning of myo
- Meaning of algos
- ^ John B. Winfield (2007), "Fibromyalgia and Related Central Sensitivity Syndromes: Twenty-five Years of Progress", Seminars in Arthritis and Rheumatism 36 (6): 335-338.
- ^ Further Legitimization Of Fibromyalgia As A True Medical Condition, Science Daily, June 25, 2007.
- ^ F. Fatma Inanici and Muhammad B. Yunus (2004), "History of fibromyalgia: Past to present", 8 (5): 369-378.
- Leavitt F, Katz RS, Mills M, Heard AR (2002). "Cognitive and Dissociative Manifestations in Fibromyalgia". J Clin Rheumatol. 8 (2): 77–84. PMID 17041327.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Frank Leavitt. "Fibrofog, Fibromyalgia and Dissociation -- Understanding why some memory-impaired patients with fibromyalgia score normally on neuropsychological testing".
- Shannon Erstad (November 10, 2005). "Nonsteroidal anti-inflammatory drugs for fibromyalgia". Health Yahoo. Retrieved 2007-10-25.
- Staud R, Robinson ME, Price DD (2005). "Isometric exercise has opposite effects on central pain mechanisms in fibromyalgia patients compared to normal controls". Pain. 118 (1–2): 176–84. PMID 16154700.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - "Late and Chronic Lyme Disease: Symptom Overlap with Chronic Fatigue Syndrome & Fibromyalgia".
- http://www.springerlink.com/content/1271314042w8405g/ Mueller W, et al. The classification of fibromyalgia syndrome. Rheumatol Int. 2007 Jul 25
- Kato K, Sullivan P, Evengård B, Pedersen N (2006). "Importance of genetic influences on chronic widespread pain". Arthritis Rheum. 54 (5): 1682–6. doi:10.1002/art.21798. PMID 16646040.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Kato K, Sullivan P, Evengård B, Pedersen N (2006). "Chronic widespread pain and its comorbidities: a population-based study". Arch. Intern. Med. 166 (15): 1649–54. PMID 16908799.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Anderberg UM, Marteinsdottir I, Theorell T, von Knorring L (2000). "The impact of life events in female patients with fibromyalgia and in female healthy controls". Eur Psychiatry. 15 (5): 33–41. PMID 10954873.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - Amital D, Fostick L, Polliack ML, Segev S, Zohar J, Rubinow A, Amital H (2006). "Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities?". J Psychosom Res. 61 (5): 663–9. PMID 17084145.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - Raphael KG, Janal MN, Nayak S (2004). "Comorbidity of fibromyalgia and posttraumatic stress disorder symptoms in a community sample of women". Pain Med. 5 (1): 33–41. PMID 14996235.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - Sarno, Dr. John E, (1998). The Mindbody Prescription: Healing the Body, Healing the Pain. pp. 76–78. ISBN 0-446-67515-6.
{{cite book}}
: CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link) - Sarno, Dr. John E.; et al. (2006). The Divided Mind: The Epidemic of Mindbody Disorders. pp. 21–22, 235–237, 294–298. ISBN 0-06-085178-3.
{{cite book}}
: Explicit use of et al. in:|first=
(help)CS1 maint: extra punctuation (link) - Selfridge, Dr. Nancy, and Peterson, Franklynn (2001). Freedom from Fibromyalgia: The 5-Week Program Proven to Conquer Pain. pp. 56–57. ISBN 0-8129-3375-3.
{{cite book}}
: CS1 maint: multiple names: authors list (link) - http://www.ncbi.nlm.nih.gov/pubmed/16816393?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.bmj.com/cgi/content/full/312/7042/1339
- http://www.ncbi.nlm.nih.gov/pubmed/15043802?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/18093615?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/18160219?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://brain.oxfordjournals.org/cgi/content/full/127/4/773
- http://www.ncbi.nlm.nih.gov/pubmed/16174484?ordinalpos=18&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/12849719?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/14975515?ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/9355111?ordinalpos=27&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/7715939?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/10597883?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.jneurosci.org/cgi/content/full/19/10/4169
- http://www.ncbi.nlm.nih.gov/pubmed/15327817?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/1611515?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/15275769?ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/6314870?ordinalpos=113&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=15975975
- http://www.ncbi.nlm.nih.gov/pubmed/17023218?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.jneurosci.org/cgi/content/full/26/42/10789
- http://www.ncbi.nlm.nih.gov/pubmed/17610577?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- Andrew J. Holman and Robin R. Myers (2005). "A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole, a Dopamine Agonist, in Patients With Fibromyalgia Receiving Concomitant Medications". Arthritis and Rheumatism. 52 (8): 2495–2505.
- http://www.ncbi.nlm.nih.gov/pubmed/1313504?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/1374252?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=16762044
- http://www.ncbi.nlm.nih.gov/pubmed/17693607?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/12122920?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- "Fibromyalgia -- An Information Booklet". Arthritis Research Campaign. October 2004.
- Anderberg, UM (1999). "Elevated plasma levels of neuropeptide Y in female fibromyalgia patients". European Journal of Pain. 3 (1): 19–30. PMID 10700334.
{{cite journal}}
: Unknown parameter|coauthors=
ignored (|author=
suggested) (help) - Jones, KD (2007). "Growth hormone perturbations in fibromyalgia: a review". Seminars in Arthritis and Rheumatism. 36 (6): 357–79. PMID 17224178.
{{cite journal}}
: Unknown parameter|coauthors=
ignored (|author=
suggested) (help) - Shuer, ML. "Fibromyalgia: symptom constellation and potential therapeutic options". Endocrine. 22 (1): 67–76. PMID 14610300.
- Yuen, KC (2007). "Is further evaluation for growth hormone (GH) deficiency necessary in fibromyalgia patients with low serum insulin-like growth factor (IGF)-I levels?". Growth hormone & IGF research. 17 (1): 82–8. PMID 17289417.
{{cite journal}}
: Unknown parameter|coauthors=
ignored (|author=
suggested) (help) - Bennett, RM. "Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia". 24 (7): 1384–9. PMID 9228141.
{{cite journal}}
: Cite has empty unknown parameter:|1=
(help); Cite journal requires|journal=
(help); Text "Journal of Rheumatology" ignored (help) - McCall-Hosenfeld, JS. "Growth hormone and insulin-like growth factor-1 concentrations in women with fibromyalgia". Journal of Rheumatology. 30: 809–14. PMID 12672204.
{{cite journal}}
: Unknown parameter|coauthors=
ignored (|author=
suggested) (help); Unknown parameter|issues=
ignored (help) - ^ Kathy Longley (2004). "Are phosphates the hidden enemy?" (PDF). Fibromyalgia Association UK. - sets out Dr St Amand's ideas Cite error: The named reference "Longley" was defined multiple times with different content (see the help page).
- http://www.ncbi.nlm.nih.gov/pubmed/9035000?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/2282545?ordinalpos=13&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- ^ Bennett RM, De Garmo P, Clark SR (1996). "A Randomized, Prospective, 12 Month Study To Compare The Efficacy Of Guaifenesin Versus Placebo In The Managment Of Fibromyalgia" (reprint). Arthritis and Rheumatism. 39: S212.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)
Lay summary and report:- Melissa Kaplan (April 19, 2007). "Is One Placebo Better Than Another? -- The Guaifenesin Story". Chronic Neuroimmune Diseases. Fibromyalgia Network.
- St. Amand, R. Paul (1997). "A Response To The Oregon Study's Implication". Clinical Bulletin of Myofascial Therapy. 2 (4). Retrieved 2007-06-23.
- Kendall SN (2004). "Remission of rosacea induced by reduction of gut transit time". Clin Exp dermatol. 29 (3): 297–9. PMID 15115515.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - Pimental M, Wallace D, Hallegua D et .al (2004). "A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing". Ann Rheum Dis. 63 (4): 450–2. PMID 15020342.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - Brown SL, Pennello G, Berg WA, Soo MS, Middleton MS (2001). "Silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women". J Rheumatol. 28 (5): 996–1003. PMID 11361228.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - "Study of Silicone Gel Breast Implant Rupture, Extracapsular Silicone, and Health Status in a Population of Women". FDA. May 29, 2001.
- Lipworth L, Tarone RE, McLaughlin JK. (2004). "Breast implants and fibromyalgia: a review of the epidemiological evidence". Ann Plast Surg. 52 (3): 284–7. PMID 15156983.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - "FDA Breast Implant Consumer Handbook 2004". FDA. June 8, 2004.
- Katz DL, Greene L, Ali A, Faridi Z (2007). "The pain of fibromyalgia syndrome is due to muscle hypoperfusion induced by regional vasomotor dysregulation". Med Hypotheses. (Epub ahead of print). doi:10.1016/j.mehy.2005.10.037. PMID 17376601.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - Frissora CL, Koch KL (2005). "Symptom overlap and comorbidity of irritable bowel syndrome with other conditions". Current gastroenterology reports. 7 (4): 264–71. PMID 16042909.
- Zipser RD, Patel S, Yahya KZ, Baisch DW, Monarch E (2003). "Presentations of adult celiac disease in a nationwide patient support group". Dig. Dis. Sci. 48 (4): 761–4. PMID 12741468.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - National Institute of Arthritis and Musculoskeletal and Skin Diseases (June 2004). "Questions and Answers About Fibromyalgia -- How Is Fibromyalgia Diagnosed?". National Institutes for Health.
- Selfridge, Dr. Nancy, and Peterson, Franklynn (2001). Freedom from Fibromyalgia: The 5-Week Program Proven to Conquer Pain. ISBN 0-8129-3375-3.
{{cite book}}
: CS1 maint: multiple names: authors list (link) - http://www.webmd.com/fibromyalgia/Cyclobenzaprine-hydrochloride-for-fibromyalgia
- http://www.fibromyalgia-reviews.com/Drg_Zanaflex.cfm
- http://www.intelihealth.com/IH/ihtIH/WSIHW000/8310/8310.html
- O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K (1999). "Antidepressant therapy for unexplained symptoms and symptom syndromes". The Journal of family practice. 48 (12): 980–90. PMID 10628579.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - http://www.ncbi.nlm.nih.gov/pubmed/7478688?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- http://www.ncbi.nlm.nih.gov/pubmed/10833553?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus
- http://www.ncbi.nlm.nih.gov/pubmed/17466657?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
- Arnold LM, Goldenberg DL, Stanford SB, et. al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007 Apr;56(4):1336-44
- Crofford LJ, Rowbotham MC, Mease PJ; et al. (2005). "Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial". Arthritis Rheum. 52 (4): 1264–73. doi:10.1002/art.20983. PMID 15818684.
{{cite journal}}
: Explicit use of et al. in:|author=
(help)CS1 maint: multiple names: authors list (link) - Andrew J. Holman and Robin R. Myers (2005). "A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole, a Dopamine Agonist, in Patients With Fibromyalgia Receiving Concomitant Medications". Arthritis and Rheumatism. 52 (8): 2495–2505.
- http://clinicaltrials.gov/ct2/show/NCT00464737
- Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C (1996). "A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia". Arthritis Rheum. 39 (11): 1852–9. PMID 8912507.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Swift W, Gates P, Dillon P (2005). "Survey of Australians using cannabis for medical purposes" (PDF). Harm reduction journal. 2: 18. doi:10.1186/1477-7517-2-18. PMID 16202145.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link) - Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R (2006). "Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief". Current medical research and opinion. 22 (7): 1269–76. doi:10.1185/030079906X112651. PMID 16834825.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Burnes TL, Ineck JR. "Cannabinoid Analgesia as a Potential New Therapeutic Option in the Treatment of Chronic Pain". Annals of Pharmacotherapy. 40 (2): 251–60. doi:10.1345/aph.1G217.
- Radbruch L, Elsner F (2005). "Emerging analgesics in cancer pain management". Expert opinion on emerging drugs. 10 (1): 151–71. PMID 15757410.
- Notcutt W, Price M, Miller R; et al. (2004). "Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies". Anaesthesia. 59 (5): 440–52. doi:10.1111/j.1365-2044.2004.03674.x. PMID 15096238.
{{cite journal}}
: Explicit use of et al. in:|author=
(help)CS1 maint: multiple names: authors list (link) - Russo EB (2004). "Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?". Neuro Endocrinol. Lett. 25 (1–2): 31–9. PMID 15159679.
- "Fibromyalgia". NORML (The National Organization for the Reform of Maijuana Laws). Retrieved 2007-10-25.
- Epsom Salts Industry Council
- Busch A, Schachter CL, Peloso PM, Bombardier C (2002). "Exercise for treating fibromyalgia syndrome". Cochrane database of systematic reviews (Online) (3): CD003786. PMID 12137713.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Berman BM, Ezzo J, Hadhazy V, Swyers JP (1999). "Is acupuncture effective in the treatment of fibromyalgia?". The Journal of family practice. 48 (3): 213–8. PMID 10086765.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Gowans SE, deHueck A (2004). "Effectiveness of exercise in management of fibromyalgia". Current opinion in rheumatology. 16 (2): 138–42. PMID 14770100.
- Gamber RG, Shores JH, Russo DP, Jimenez C, Rubin BR (2002). "Osteopathic manipulative treatment in conjunction with medication relieves pain associated with fibromyalgia syndrome: results of a randomized clinical pilot project" (PDF). The Journal of the American Osteopathic Association. 102 (6): 321–5. PMID 12090649.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Sarno, Dr. John E; et al. (2006). The Divided Mind: The Epidemic of Mindbody Disorders. ReganBooks. pp. 21–22, 235–237, 264–265, 294–298, 315, 319–320, 363. ISBN 0-06-085178-3.
{{cite book}}
: Explicit use of et al. in:|first=
(help) - Leonard-Segal, Dr. Andrea (2006). "A Rheumatologist's Experience With Psychosomatic Disorders". The Divided Mind: The Epidemic of Mindbody Disorders. ReganBooks. pp. 264–265. ISBN 0-06-085178-3.
- Smith et al, Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins, Ann Pharmacother. 2001 Jun;35(6):702-6.
- Forest Laboratories (May 22, 2007). "Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome".
- Robert Bennett. "Speculation as to the mechanism whereby some of Dr. St. Amand's fibromyalgia patients experienced improvement while taking guaifenesin". Fibromyalgia Information
Foundation. Retrieved 2008-01-06.
{{cite web}}
: line feed character in|publisher=
at position 25 (help) - St. Amand, R. Paul (1997). "A Response To The Oregon Study's Implication". Clinical Bulletin of Myofascial Therapy. 2 (4). Retrieved 2007-06-23.
- Staud R, Vierck CJ, Robinson ME, Price DD (2005). "Effects of the N-methyl-D-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects". The journal of pain : official journal of the American Pain Society. 6 (5): 323–32. doi:10.1016/j.jpain.2005.01.357. PMID 15890634.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - Salynn Boyles (May 23, 2005). "Cough Drug May Help Fibromyalgia Pain: Findings Could Affect Other Chronic Pain Conditions". WebMD.
- The Fibromyalgia Association of the UK
Further reading
External links
- US Food and Drug Administration Living with Fibromyalgia, First Drug ApprovedJune 21, 2007
- Template:Dmoz
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. "Questions and Answers About Fibromyalgia". Retrieved 2007-06-01.
- "The National Fibromyalgia Association U.S". 2007. Retrieved 2007-06-01.
- "Fibromyalgia Resource Information". 2005. Retrieved 2007-06-01.
- Fybromyalgia-CFS-NorthEast-uk UK-based support group on Webjam
Diseases of joints | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
General | |||||||||||
Symptoms | |||||||||||
Inflammatory |
| ||||||||||
Noninflammatory |